• Home
  • Latest
  • Fortune 500
  • Finance
  • Tech
  • Leadership
  • Lifestyle
  • Rankings
  • Multimedia
Healthopioid epidemic

6 More States Just Sued the Oxycontin Maker. How It Could Dramatically Alter the Price of an Opioid Settlement

By
Bloomberg
Bloomberg
Down Arrow Button Icon
By
Bloomberg
Bloomberg
Down Arrow Button Icon
May 16, 2018, 6:00 AM ET

Lawsuits filed against Oxycontin maker Purdue Pharma and other drugmakers by Tennessee and Florida cast more doubt about the viability of settlement talks aimed at addressing the U.S. opioid epidemic.

Tennessee Attorney General Herbert Slatery and Florida’s Pam Bondi on Tuesday accused executives of Purdue and other opioid makers and distributors of fueling a public-health crisis by falsely claiming that the synthetic pain medicine wasn’t addictive. They joined more than 20 other states that have sued companies including Purdue, Johnson & Johnson (JNJ) and McKesson Corp. (MCK) over the products.

It’s a twist for Slatery and Bondi, who have been leading settlement negotiations sponsored by a coalition of attorneys general and who’ve deferred from suing makers and distributors of the drug until now. Four other states — North Carolina, Texas, Nevada and North Dakota — also filed opioid suits Tuesday. They were also part of the talks.

“We are disappointed that after months of good faith negotiations working toward a meaningful resolution to help these states address the opioid crisis, this group of attorneys general have unilaterally decided to pursue a costly and protracted litigation process,” Robert Josephson, a Purdue spokesman, said in an emailed statement.

Separately, hundreds of cities and counties are suing the drugmakers and distributors in cases that have been consolidated before a federal judge in Cleveland. The first trial there is scheduled for March, although settlement talks continue.

Quick Settlement?

Lawyers for Stamford, Conn.-based Purdue approached some state attorneys general last year hoping to come up with a quick and affordable settlement of lawsuits seeking to recoup the costs of dealing with the fallout from opioid addictions.

But six people familiar with the talks said this month they were stalled over the question of who will pay to provide extra funding for law-enforcement and drug treatment budgets, Bloomberg News reported May 3. The companies want to test their defenses to the state’s claims before discussing a multibillion-dollar settlement, the people said.

Slatery’s and Bondi’s decision to sue is an acknowledgment opioid makers and distributors won’t get serious about settling suits until the cases go to trial, said Mike Papantonio, a Florida-based lawyer involved in the litigation.

“You can’t accomplish anything in terms of getting companies to admit they are responsible without filing lawsuits,” Papantonio said. “There won’t be any closure on this without litigation.”

Leigh Ann Jones, Slatery’s spokeswoman, said Tennessee’s top lawyer “will continue to play a leadership role in the multistate effort and settlement discussions.”

Bondi said she wanted an out-of-court deal even though she’d joined the ranks of states suing opioid makers. “We will never stop negotiating,” she said at a press conference Tuesday. The suit is a warning that Florida officials are “fully prepared to go to war” if the companies balk at a settlement, she added.

George Jepsen, Connecticut’s attorney general and another leader of the multistate talks, said Slatery and Bondi should press ahead with settlement talks. “We anticipate they will continue in their leadership rolls going forward,” he said.

Other attorneys general have dropped out of the talks because they wanted to move aggressively to recover the billions of dollars spent on the opioid crisis. More than 100 Americans die daily from opioid overdoses.

The consolidated case by the cities and counties is In Re: National Prescription Opiate Litigation, 17-md-2804, U.S. District Court, Northern District of Ohio (Cleveland).

About the Author
By Bloomberg
See full bioRight Arrow Button Icon

Latest in Health

Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025

Most Popular

Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Fortune Secondary Logo
Rankings
  • 100 Best Companies
  • Fortune 500
  • Global 500
  • Fortune 500 Europe
  • Most Powerful Women
  • Future 50
  • World’s Most Admired Companies
  • See All Rankings
Sections
  • Finance
  • Fortune Crypto
  • Features
  • Leadership
  • Health
  • Commentary
  • Success
  • Retail
  • Mpw
  • Tech
  • Lifestyle
  • CEO Initiative
  • Asia
  • Politics
  • Conferences
  • Europe
  • Newsletters
  • Personal Finance
  • Environment
  • Magazine
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms Of Use
  • Single Issues For Purchase
  • International Print
Commercial Services
  • Advertising
  • Fortune Brand Studio
  • Fortune Analytics
  • Fortune Conferences
  • Business Development
  • Group Subscriptions
About Us
  • About Us
  • Editorial Calendar
  • Press Center
  • Work At Fortune
  • Diversity And Inclusion
  • Terms And Conditions
  • Site Map
  • About Us
  • Editorial Calendar
  • Press Center
  • Work At Fortune
  • Diversity And Inclusion
  • Terms And Conditions
  • Site Map
  • Facebook icon
  • Twitter icon
  • LinkedIn icon
  • Instagram icon
  • Pinterest icon

Latest in Health

Toryo Ito, the vice abbot of the oldest Zen temple in Kyoto
SuccessCareers
Buddhist monk says workers struggle to wind down from fast-paced office culture—he shares a 30-second tip to reset your nervous system
By Emma BurleighMarch 29, 2026
14 hours ago
Big TechHealth
Are you addicted to technology? 6 questions experts use to help spot red flags
By Kristin StollerMarch 28, 2026
2 days ago
HealthDietary Supplements
The Best Omega-3 Supplements (2026): An Expert Guide
By Emily PharesMarch 27, 2026
2 days ago
HealthDietary Supplements
The 5 Best Online Dietitians of 2026: Help to Reach Your Nutrition Goals
By Christina SnyderMarch 27, 2026
2 days ago
HealthDietary Supplements
Ritual Vitamins Review (2026): With Insight from an Expert
By Emily PharesMarch 27, 2026
2 days ago
HealthDietary Supplements
The 4 Best Matcha Powders of 2026: Taste Tested by Our Team
By Emily PharesMarch 27, 2026
2 days ago

Most Popular

Europe
413,793 KitKat bars stolen: 'Whilst we appreciate the criminals’ exceptional taste, the fact remains that cargo theft is an escalating issue'
By Fortune EditorsMarch 28, 2026
1 day ago
Energy
Saudi pipeline to bypass Hormuz hits 7 million barrel goal
By Fortune EditorsMarch 28, 2026
24 hours ago
Economy
U.S. debt suddenly draws weaker demand as $10 trillion must be rolled over this year amid Iran war. 'The bond market remains undefeated'
By Fortune EditorsMarch 28, 2026
1 day ago
Success
Meetings are not work, says Southwest Airlines CEO—and he’s taking action by blocking his calendar every afternoon from Wednesday to Friday 
By Fortune EditorsMarch 27, 2026
3 days ago
Energy
Elon Musk warns the U.S. could soon be producing more chips than we can turn on. And China doesn’t have the same issue
By Fortune EditorsMarch 29, 2026
9 hours ago
Economy
The stay-at-home boyfriend is now an economic trend as more women than men go to work
By Fortune EditorsMarch 28, 2026
1 day ago

© 2026 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
FORTUNE is a trademark of Fortune Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.